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INTRODUCTION

Fever,

the abnormal elevation of central body

temperature,

is a common accompaniment of many clinically

recognized pathologic states.
neoplastic diseases,
accidents,

connective tissue disorders, vascular

hemolytic states,

and metabolic abnormalities.
fever production,

Among these are infections,

drug or chemical reactions,
(11).

A mechanism for

involving endogenous pyrogen production

and release by host cells in response to an appropriate
stimulus, has been proposed on the basis of evidence
derived from many experimental situations,

induced

primarily in laboratory animals, occasionally in man (4).
While it has been assumed that the same mechanism is
involved in the production of fever in the above mentioned
clinical states, direct evidence for this assumption is
not extensive.

The following work is an attempt to relate

the fever of Hodgkin’s Disease,
by fever,

a disease often characterized

to the proposed mechanism of fever production

involving endogenous pyrogen.

.

,
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Fever and Neoplastic Disease

Fevers often complicate the course of patients with
neoplastic diseases

(22,

27,

28).

However,

while the

overall incidence of fever in cancer patients is high,
the significance of the fever to the patient’s course is
often low (27).

Various series reviewed by Boggs and

Frei (22) and Browder,

et.

al.,

(28) covering patients

with various, primarily internal, solid tumors,

showed

the incidence of fever in these patients to be over

>40%,

Most of these fevers, however, were isolated rises in
temperature.
instance,

In only 3% of Briggs’

for

was the fever deemed to be a prominent

feature of the patient’s course
the fever,

patients,

in most cases,

(27).

Furthermore,

could be ascribed to a coin¬

cident infection, often secondary to obstruction caused
by the tumor.

Browder, et. al.,

in carefully examining

their series of febrile cancer patients,

concluded

that fever in the absence of infection or obstruction
was indeed rare.

They explained the earlier reports

of high fever incidence among these patients by the
high incidence of infection and obstruction amongst
patients with these cancers, particularly those with
cancer of the lung or of the gastrointestinal tract.
In their series,

they were able to find only 5^% of 351

patients who had fever related to their disease, without
infection or obstruction

(28).

For the most part,

then,

the problem of explaining fever in neoplastic disease is

«

.

.
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really a problem of explaining fever in infection.
There are, however, certain exceptions.
sease metastatic to the liver.

One is di¬

In Browder’s group,

the

incidence of fever in the absence of demonstrable infection
was two and one half times greater among patients with
hepatic metastases

(28).

Earlier, Penster and Klatskin

had found that 23$ of their febrile patients with carcinoma
or sarcoma metastatic to the liver had fever unassociated
with infection (40).
Other exceptions are those certain neoplasms whose
presence is often early associated with fever, and often
without associated infection, obstruction or hepatic
metastasis.
24,

31,

44,

Among these are renal cell carcinoma,
62,

In 1929,

99), and Hodgkin’s Disease

(22,

(14,

65,

90,

Creevy reported two cases of fever associated

with malignant renal tumors, one in which there was no
metastatic disease, and concluded that,

since the fever

could not be related to necrosis in the tumor nor to
metastasis,

it was due to a product of the abnormal

metabolism of the tumor tissue

(35).

Since that time,

there have been reports placing the incidence of fever
in patients with this tumor at between ten and twenty
percent

(31,

and Sinkoff

91).

24,

44).

(In a review of 273 cases Berger

(14) put the incidence at 16%,)

The fever

is often found in the absence of extensive hemorrhage

.

h

or necrosis in the tumor,
disease,

in the absence of metastatic

without relation to the size of the tumor or the

extent of local invasion,

(62) and, as can be attributed

by the frequency with which patients with this tumor
are included amongst series of patients with fever
of unknown etiology

(23,

24,

41,

51,

6l,

79,

83,

99),

is often the presenting symptom of the disease.

it

Moreover,

the fever is so predictably relieved by removal of the
tumor,

that persistence of the fever after operation

for resection of the primary, or its recurrence at some
later date,
disease

suggest the presence of undiscovered metastatic

(74).

The fever associated with Hodgkin’s Disease has been
a particularly intriguing aspect of the clinical picture
of that disease for over 100 years.

Among the first

patients described by Hodgkin in 1832 was a 25-year-old
woman who had two intermittent attacks of fever
In 1858,
by Wilke,

(52).

shortly after the rediscovery of Hodgkin’s work
Wunderlich described a patient in whom there

were periodic temperature elevations coincident with
enlargement of the lymph nodes and spleen (101).

In

1870, Murchison described a six-year-old with a two
and one half year course of periodic febrile episodes,
which also were associated with nodal enlargement
In 1879,
in

40

(32).

Gowers gathered 113 cases of Hodgkin's Disease,

of whom attention had been paid to the

temperature(45).

.

.
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Twenty-seven had fever which could be related to
the clinically determined activity of the disease, and
only thirteen were afebrile or had fever attributable
to an intercurrent infection.

He was the first to

draw attention to that unusual and interesting pattern of
relapsing fever which was to be frequently reported in
the ensuing years and to become widely known as PelEbstein-Murchison fever.

In this pattern,

of fever which gradually builds in degree,
recedes by lysis, not by crisis,

several days
then gradually

is followed by a period

of normal or subnormal temperatures.

He also described

two other, more common, patterns of fever in these
patients-continuous, with minimal diurnal variation, and
intermittent,

with evening exacerbations.

many reports of the more interesting,
pattern.

There followed

but rarer, relapsing

Osier described a case with intervals of fever

associated with fluctuating lymph node size,
with the degree of pyrexia,
afebrile periods

(67).

increasing

decreasing during the

Pel earned his eponym with a

description of a 25-year-old man who had five episodes of
fever lasting between ten and 31 days, associated with
increasing splenic size
a case,

(78).

In 1887, Ebstein reported

followed for 238 days, during which there were

nine attacks of fever, of two weeks duration, spaced by
afebrile intervals, of ten or eleven days

(38).

In 1904,

„

*
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Taylor reported three more cases with the relapsing
type of fever,

including one gentleman whom he had

followed through five febrile episodes of seven to thirty
days duration with afebrile intervals of six to seventeen
days,

who then remained afebrile for four months before

his eventual death

(96).

He was the first to point out

that of the three patterns of fever in Hodgkin’s Disease
patients as described by Gowers-continuous,
and relapsing,

the last was most rare,

the most pathognomonic of the disease.

intermittent,

but when present,
In 1911, MacNalty

gathered together 27 cases of relapsing fever in Hodgkin’s
Disease reported in the literature and added five of his
own,

using the eponym Pel-Ebstein-Murchison fever to

describe them (67).
More recent studies have been concerned with the
significance of fever in Hodgkin’s Disease patients.
Lobell,

ejt.al,

found that 60% of Hodgkin’s Disease

patients have fever

(defined as a single reading greater

than 103°F or a temperature greater than 100.4° for three
of five consecutive days) at some point during the course
of their disease

(65).

Looking at the biased sample of

hospitalized patients, Boggs and Frei found that Hodgkin’s
Disease patients have the highest rate of febrile days to
total hospitalized days amongst patients with neoplastic
diseases,

and that the fever in these patients was more

likely to be unassociated with demonstrable infection than
in patients with other lymphomas,

leukemias,

or solid tumors

(22).

-
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In Lobell's study,

fever was classified as infection-

related or disease-related.

One half the patients followed

in their clinic had disease-related fever at some point
in their course,

while only 13% had fever related to

documented infection.
diagnosis

Fever present at the time of

(one third of their patients were in this group)

was almost exclusively disease-related.
course of the disease, however, a

Even late in the

patient with fever was

more likely to have the fever of Hodgkin's disease than
to have fever secondary to infection.
They also found that fever is a bad prognostic in¬
dicator independent of certain other bad prognostic signs,
that the fever thought to be disease-related could not be
distinguished from the fever of infection by the character
of the temperature chart alone,

and that Pel-Ebstein-

Murchison fever is indeed rare,

being present in only one

of their 137 patients.

i'

„
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Mechanism of Fever

Fever is the abnormal elevation of central body
temperature.

It may be brought about by direct activation

of peripheral mechanisms that increase heat production or
reduce h at loss,

but more often is the result of a central

alteration of body temperature regulation (32,

33).

Body

temperature is normally maintained relatively constant by
regulation of heat production and heat loss.

This is

thought to be a funct ±>n of certain centers in the hypo¬
thalamus which act in response to peripheral and central
thermoreceptor input.

During fever, regulation of body

temperature appears to proceed in a normal fashion,
at an altered set point

(4,

33*100).

but

The mechanism by

which a new set point is established is not entirely known,
but it appears,

in many animal models,

that a common pathway

is the release of endogenous pyrogen (EP)
pherally,

by cells peri¬

and its action at some point centrally

(4).

Evidence for this pathway consists of demonstration
of EP production by cells from the periphery,
of circulating EP,

demonstration

and demonstration of central effect.

In

many experimental systems various exogenous and endogenous
pyrogens including Gram negative bacterial endotoxins, gram
positive bacteria, viruses, antigen-antibody complexes, and
antigens have been shown to effect the production and
release of an endogenous pyrogen from cells capable of its

o

■

-

s
production (4,

6,

30,

85,

94).

found in many of these systems,

Circulating EP has been
including induced strepto-

coccul and pneumococcal infections,
of virus,

intravenous injections

intravenous injection of endotoxin,

and intravenous

injection of antigen or antigen-antibody complexes
46,

71,

85).

(4,

9,

Centrally, EP has been shown to induce fever

upon anterior intrathecal injection of one percent of the
amount required to produce a similar effect by IV injection,
and to produce changes in the firing pattern of thermosen¬
sitive neurons in this area similar to those seen upon local
cooling

(4, 100).

It is presently unclear whether endogenous pyrogen
represents the final common pathway or merely a common
pathway for elevation of the set point by many varied
stimuli.

Its effect at the hypothalamus may very likely

be mediated locally by other intra or extra cellular
messengers, as is the effect of hormones at their target
tissues

(100).

To summarize,

the postulated mechanism of fever pro¬

duction involves the interaction of an appropriate stimulus
with a cell capable of production and release of endogenous
pyrogen leading to the release of this mediator.

EP travel

via the bloodstream to the anterior hypothalamus where,
possibly via the release of other substances,

it causes a

change in the pattern of neuron discharge which effects net
heat accumulation,

elevation of central body temperature.

.

.
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and maintenance of this new termperature level.

Endogenous Pyrogen

Endogenous pyrogen is a protein-containing substance
of molecular weight between ten and twenty thousand
63,

73).

(21,

It has been shown to be produced by a number of

cell types.

Blood leukocytes were early recognized as a

source of EP.

In 1948, Beeson first isolated a pyrogen-

producing substance from rabbit granulocytes and subsequently,
together with Bennett,

in the classic article in the field,

distinguished th js pyrogen from bacterial endotoxin (11,
13).

They were unable to isolate EP from other cells.

Gerbrandy,

Cranston,

12,
Later,

and Snell demonstrated that pyrogen

released human blood was a variable, dependent on the
granulocyte content of that blood
However,

(42).

situations were recognized in which EP

release by cells other than polymorphonuclear leukocytes
had to be postulated.

Included were fever in agranulocy¬

tosis and in inflammatory processes characterized predominantly
by a mononuclear response such as the granulomatous diseases,
including Hodgkin’s disease

(13).

It has since been shown that cells other than poly¬
morphonuclear leukocytes are endogenous pyrogen producers.
Mononuclear cells from rabbit lung, and from experimentally
produced steril exudates,
in vitro

(5,

49).

produce EP when suitably activated

Also human blood monocytes,

from normal

-

,

-
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individuals or patients with monocytosis
hepatic Kupfer cells

(19), and rabbit

(36) have been shown to release EP

in vitro when activated.

The presence of pyrogen in

tissue monocytes may be the explanation for the pyrogenic
activity of saline extracts from normal rabbit tissues
(10,

93a).

Circulating human eosinophils have recently

been shown to release EP when activated in vitro by phag¬
ocytosis or bacterial endotoxin (69).
and Atkins,

by Root, et_.

Studies by Snell

al, and by Kammermeyer,

et_. al,

have failed to demonstrate EP release by circulating,
lymph node, or cultured lymphocytes
cytes have,

however,

(4,

56,

84).

Lympho¬

been shown to produce a substance

capable of provoking EP release from competent cells

(7).

Endogenous pyrogen production by PMN leukocytes only
occurs following cell stimulation (17,

74,

55).

Although

the exudate granulocyte has been found to be spontaneously
active,

an activator has been isolated from the exudate

fluid which is presumably res pnsible

(70).

Activation of

PMN leukocytes may follow stimulation by endotoxin,
phagocytosis,

antigen-antibody complexes in the presence

of complement, or, perhaps,
^2,

74,

94,

100).

An early,

by lymphokine mediator

(3,

7,

34,

essential response of the cell

to stimulation is new RNA and protein synthesis.

Measurable

EP release begins at about two hours after activation
and continues for only 12-16 hours.

Release of EP may be

.

.
:

.
»
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suppressed by agents that block protein synthesis or
glycolytic pathways only if such agents are added
during the initial two-hour period after the activation
(17,

7^).
Blood and tissue monocytes appear to behave differently

in several respects

(5,

15,

19).

They release 4-10 times

the amount of pyrogen for the same stimulus as do PMN
leukocytes and they continue pyrogen release longer after
activation, perhaps 48-72 hours.

Also,

throughout this

period, pyrogen production by these cells can be suppressed
by inhibitors of protein synthesis.

Mechanism of Hypersensitivity Fever

Clinical association between fever and hypersensitivity
reaction has been long recognized, as in conditions such
as serum sickness and drug reactions

(4).

Experimentally,

injection of an antigen into a sensitized animal will result
in fever

(71).

this response.

Serum antibody appears to be essential to
Wolff’s group has suggested that it is the

antigen-antibody complex which is the stimulus to endogenous
pyrogen production in this situation, as antigen-antibody
complexes prepared in vitro produced fever when injected into
unsensitized animals

(71,

85).

Attempts to produce EP

release by blood cells i_n vitro using antigen-antibody
complexes has usually been unsuccessful.

Atkins failed to

induce EP production using complexes of bovine gamma globulin

*
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(BGG)

and rabbit anti-BGG prepared in antigen excess

(7).

In other experiments, when the benzyl penicilloyl nucleus
of penicillin was incubated with serum and cells from
sensitized animals, Atkins and Chusid were able to demonstrate
EP release.

The exact nature of this hypersensitivity

reaction was not defined, however

(30).

Fever production has also been studies in systems of
delayed hypersensitivity.

Injection of Old Tuberculin causes

fever in tuberculin sensitive rabbits, and this response
can be transferred to non-sensitized rabbits by mononuclear
cells as well as by serum

(4,

50,

50a).

Blood leukocytes

and tissue macrophages from tuberculin-sensitized animals
release EP upon in vitro incubation with antigen (5,

8).

This suggests that antigen has a direct effect upon poly¬
morphonuclear and mononuclear cells,
Recently,

inducing EP release.

using another model Atkins,

et_.

al,

demon¬

strated a role for lymphocytes as mediators leading to
endogenous pyrogen release in a system of delayed hyper¬
sensitivity.

Rabbits were immunized to dinitrophenol

conjugated bovine serum albumin,
globulin,

(DNP)-

to DNP-bovine gamma

or to human serum albumin.

Upon incubation of

lymph node lymphocytes obtained from these sensitized animals
with the appropriate antigen, a substance, perhaps a lymphokine was released which,

while not itself pyrogenic,

the release of EP from normal blood ]eukocytes

(3,

7).

induced

.
,

•>
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Clinical Fever and Endogenous Pyrogens

Although the mechanisms of EP production discussed
above have been postulated to account for clinical fever
in man,

there is little experimental evidence for this

hypothesis

(4).

Such evidence ought to include

(1.)

demonstration of endogenous pyrogen production by human
cells in response to appropriate stimuli,

(2.) isolation

of EP from patients with diseases characterized by fever,
(3.) detection of EP in the circulation in association with
fever, and

(4.)

induction of fever by EP administration.

Several human cell types have been shown to produce
endogenous pyrogens in vitro.
blood monocytes,

eosinophils,

Polymorphonuclear leukocytes,
and spleen and lymph node

mononuclear cells are all capable of EP release if suitably
stimulated by phagocytosis

(16,

19,

69,

74).

lymph node cells, predominantly mononuclear,

Spleen and
are occasionally

"spontaneously" active in vitro, unlike the other cell types
which require activation (16).

In addition, cell suspensions

from renal cell carcinomas have been found,

by Bodel,

to be

capable of EP release during in vitro incubation (15).
Several studies have demonstrated the presence of an
endogenous pyrogen in fluids obtained from patients,
not always febrile ones.
of a pyrogen,

In 1962,

Snell reported the presence

with properties characteristic of EP,

exudate fluid from malignant,

although

in

bacterial, and tuberculous

.

,

,
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effusions

(93).

A similar substance was not present in

transudates from patients in congestive heart failure.
However,

there was no correlation between EP isolation

and the presence of fever in the patient.
Hollingsworth reported that a pyrogen,

Bodel and

active in rabbits,

was present in the joint fluids of patients with such
diseases as rheumatoid arthritis, acute rheumatic fever,
pseudogout, Reiter's syndrome,
(20).

and metastatic carcinoma

Sokal and Shimaoka have demonstrated a pyrogen in

the urine of febrile patients with Hodgkin's disease and
another febrile patient,
controls

(95).

not present in the urine of normal

Finally, Rawlins, et. al,

found a similar

pyrogen in renal carcinoma tissue (82).
The a arch for circulating endogenous pyrogen in
clinical febrile states has been uniformly unsuccessful.
Snell was unable to demonstrate circulating EP by re¬
infusion of plasma taken from patient febrile with various
infections

(92).

Bouruncle and Doan tried reinfusing 500

ml. of whole blood from patients febrile to 103° F with
periodic fever, and,

similarly, failed to induce fever in

these same patients,

when they had become afebrile (25).

Sokal and Shimaoka were unable to produce fever by
reinfusion of plasma obtained from febrile Hodgkin's disease
patients

(95).

Cranston, using malaria patients,

was

able to invoke fever on reinfusion of the cellular elements.

.

„
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but not the plasma;

this result seems more likely

due to the host response to altered cells, or to the
parasite,

than to a preformed pyrogen (32).

Since Bodel and Atkins have shown that human
endogenous pyrogen can be assayed in rabbits

(18),

the

necessity for reinfusion studies has been eliminated,
but the results have not changed.

Greisman, et.al, using

a rabbit assay that permitted pyrogen testing up to
20 ml.

of human plasma in rabbits, after absorbing out

the hemagglutinins,

were unable to demonstrate a pyrogen

in plasma drawn from febrile

(104° - 105°F) patients with

Rocky Mountain Spotted Fever

(147).

Even when febrile reactions have been experimentally
induced in humans,

circulating EP has not been found.

Until recently there was only one encouraging result
reported.

Whole blood taken from a volunteer at the

height of a fever
killed E.

coli,

(38.2°C)

caused by an injection of heat

induced an early (20 minute onset) fever

in a second subject of the same blood group.

Subsequently

attempts have been made to find circulating EP by cross
infusion or reinfusion of cells or plasma from subjects
febrile due to EP infusion,

11-keto-pregnanolone infusion

and S. typhosa endotoxin injection
These all have failed.

(43,

47,

59*

8l).

.

.
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Most recently,
early

Greisman and Hornick have produced an

(45 minute onset,

90 minute peak)

temperature elevation

by infusion of 750 ml. of plasma pooled from three donors
made febrile to 102°P by S.

typhosa endotoxin (47).

While the proposed mechanism for fever production via
endogenous pyrogen release requires that EP be present, at
some time in circulating blood,

the failure to demonstrate

it there does not necessarily imply that it is never present.
Perhaps the failure to demonstrate it in these many experi¬
mental and clinical situations relates to the amount of
pyrogen present in the fluid sampled,

its distribution in

the sample with respect to protein binding,

the time of

sampling with respect to fever present in the donor, or the
failure of the assay method to reproduce a physiologic
method of presentation of the pyrogen to its receptor at
the hypothalamus.
Cranston’s group showed that endogenous pyrogen
produces fever in man when they infused EP prepared by
endotoxin stimulation of blood cells

(34,

42,

8l).

Fever in Malignant Disease

The relation between the fever of malignant disease
and the proposed mechanism of fever discussed above, is
largely unknown.

Clinically, most fevers in cancer patients

•
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are related to infection

(28).

Thus inflammation, necrosis,

and immune reaction may all be present and all of these
processes have been experimentally linked to EP production
(4,

53).

However,

there are some tumors, discussed pre¬

viously, which appear to be more frequently associated with
fever in the absence of demonstrable infection.

These

tumors, which include renal cell carcinoma and Hodgkin’s
disease have received particular attention because of the
possibility that fever in these states might be definitively
associated with endogenous pyrogen.
Rawlins, e_t al,detected an endogenous pyrogen in
tumor extracts from two febrile patients with renal cell
carcinoma (82).

They found no EP in normal kidney,

in par¬

tially necrotic tumor tissue from one afebrile patient with
renal cell carcinoma, or produced by circulating leukocytes
from the febrile patients.
renal carcinomas,

Bodel has found that cells from

which have not been previously irradiated,

spontaneously release EP upon incubation in tissue culture
medium containing patient serum, whereas cells from irradi¬
ated tumors, even when necrotic, and cells from adjacent
normal kidney produce little or none
EP release has not, however,
of fever in the patient.

(15).

This in vitro

correlated with the presence

It appears that there are other

factors beyond capacity for EP release which determine
whether the capacity for EP release becomes manifest as

.
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fever in the patient.

Activation may be one important

factor, as the cells may require a specific stimulating event
in vivo.

Other factors may be rate of absorption into

the circulation,

suppression of EP production in vivo,

inactivation of the pyrogen itself in the circulation or
at the target tissue, or modification of the target tissue’s
response to the EP stimulation.
Since renal cell carcinoma has been widely implicated
in other paraneoplastic syndromes related to the elaboration
of a protein or peptide by tumor tissue, it may be that the
tumor cells themselves are synthesizing EP.

However,

the

pyrogen may be from inflammatory cells present in the tissue,
although,

if such were the case, one would expect EP

production from cells in the previously irradiated kidney
tumor as well.
In one case of neuroblastoma,
associated with fever

which is also frequently

(39)> Chassin and Bodel were unable

to demonstrate EP release after 72 hour incubation of tumor
cells from a febrile patient
which,

(19a).

However,

this tumor,

like the pheochromocytoma, makes vasoactive amines,

may cause fever by vasoconstriction and decreased heat loss,
thus altering the efferent, rather than the afferent limb
of the termperature regulatory process.
The first observation concerning an endogenous pyrogen
in Hodgkin's disease patients was made by Sokal and Shimaoka
in 1967

(95).

Like other investigators trying to demonstrate

.
.

.

.
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circulating EP in febrile patients they were unable to
demonstrate EP in the plasma of febrile Hodgkin’s disease
patients.

They had attempted this by reinfusion of

autologous plasma to these patients when afebrile.
in examining urine concentrates,

they found a

capable of causing fever in rabbits.

However,

pyrogen

Concentrates

representing 0.03 - 1,0% of a twenty four hour urine
collection from six of seven febrile patients caused
fever in rabbits, whereas none of four concentrates from
normal controls caused fever.

They did not examine the

urine of afebrile Hodgkin's patients.
a febrile,

A concentrate from

non-Hodgkin’s diseased patient behaved similarly

to that from the febrile Hodgkin’s patients.

In each case

the fever curve obtained was characteristic of that caused
by EP, with a rapid onset after injection, and a peak at
one hour.

There was suppression but not elimination of

the fever when the material was tested in endotoxintolerant rabbits; repeated injections of the pyrogen daily
for one month caused no tolerance.
In 1971, Young and Hodas described,
the isolation of a

in an abstract,

protein from the urine of febrile

Hodgkin's disease patients which was not present in the
urine of afebrile patients with the disease
material behaves, under electrophoresis,

(101).

This

like a protein

which is pre$ nt in normal cerebrospinal fluid and in the

.

.
.

.

.

.

.

.
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plasma of febrile Hodgkin’s patients.

It has a molecular

weight of 15,000 similar to that described for endogenous
pyrogen (21,
of 10,

63,

73),

but also has an isoelectric point

which is unlike any described for EP.

point for human EP is about 7.0

(73)•

The isoelectric

It is unclear

whether this protein can be related to EP, and its signi¬
ficance remains obscure in the absence of any demonstration
of pyrogenicity.
Most recently, Bodel has examined the capacity of
various tissues from patients with Hodgkin’s disease to
produce endogenous pyrogen (15, 16).

Blood leukocytes

from these patients were indistinguishable from normal
donor’s leukocytes in that they did not spontaneously
produce pyrogen,
phagocytosis.

but invariably did so when activated by

However,

lymph node and spleen cells from

patients with lymphomas released EP upon in vitro incubation
in tissue culture medium.

Spleen cells from patients

with non-malignant splenomegaly did not release EP spon¬
taneously,

but did so in response to phagocytosis.

Since

production of EP continued for 48-72 hours in lymph node
suspensions and since this production was sensitive to
inhibition by puromycin, mononuclear cells appear to be
responsible for pyrogen production in this tissue.
spleen cells,

In

the production of pyrogen did not correlate

with percentage of granulocytes in the preparation;

,

'

O

1
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however since cycloheximide was only partially inhibitory,
both polymorphonuclear and mononuclear leukocytes may
contribute to EP release by this tissue.

The production

of EP did not correlate with presence of clinical fever
in the patient,

nor with pathological evidence of tissue

involvement by the disease.

.

.
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Hypersensitivity and the Pathogenesis of Hodgkin* s Disease

The histology of Hodgkin's disease is such that
there has long been question as to whether the process is
neoplastic or granulomatous

(58).

The Jackson and Parker

classification graded the histology from paragranuloma
to sarcoma with the prognosis being better for the paragranulomatous type than for the more frankly malignant
sarcomatous

(54).

The Lukes and Butler classification

takes account of the different histories of the patients
with different histologic lesions in its progression from a
lymphocyte predominance type with a better prognosis to the
lymphocyte depletion type with a worse one

(66).

It appears

that the lymphocytes may represent a reactive element in the
tissue whose presence can be correlated with a longer sur¬
vival.

The cells predominating in the lymphocyte depleted

lesion,

the reticulum cells and the Reed-Sternberg cells,

appear to be proliferative elements, perhaps the neoplastic
cell line whose predominance is correlated with a poorer
survival.

The suggestion is that the disease represents a

mixed reactive-proliferative state,

that the reactive

element is the earlier one, and that it in some way may lead
to or be replaced by the later proliferative state.
These observations have suggested to many a resemblance

.

.

.

.
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between Hodgkin's disease and a graft versus host reaction
(58,

97,

29).

Smithers and Kaplan,

in 1959,

first pro¬

posed that the proliferative elements were lymphocytes
that had lost some of their antigenic determinants,

and

therefore recognized normal host cells as foreign, leading
to a reaction against the host and their own proliferation
(58).

Tyler,

in i960, made a similar proposal

(97).

Since

then Schwartz and his colleagues, as well as others, have
provided a strong experimental model for lymphomas resulting
from chronic graft versus host disease

(2,

64,

87, 88,

89).

The requirements for producing the disease are an
immunocompetent graft,

a host antigen recognized as foreign,

and an immunoincompetent host.

In experimental models,

the first is provided by a parental spleen cell implantation,
the second by the antigens of the other
pressed by the

hybrid,

parent strain ex¬

and the third by a tolerant F^

hybrid or an immunosuppressed adult animal.

The result is

an early lymphoid reaction and late lymphocyte depletion,
repopulation of the area by plasma cells and reticulum cells,
and,

in a certain percentage of cases, a proliferative

reticulum cell or plasma cell population.

There is also

splenomegaly and lymphadenopathy clinically,
temic immune responsiveness, and,

impaired sys¬

in some models, auto¬

immune hemolytic anemias or immune complex glomerulonephritides

(68).

.

.
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An interesting finding,

by the Schwartz group,

is

that the proliferative cells are not of the immunocom¬
petent parent line,
(89).

but of the immunoincompetent host line

Apparently the host cells are stimulated by the

immunocompetent cells, or by the damage they cause,
undergo neoplastic transformation.

to

This may be by mutation,

such as if the products of lymphocyte breakdown cause
mutation that leads to a loss of proliferative regulation.
It also may be that the immunodepression caused by the graft
versus host disease allows the proliferation of cells
containing a viral oncogene.
origin,

These cells could be of host

but would also perhaps be recognizable by a viral-

associated antigen which they might display.
Recently, Order, et_ al, demonstrated by immunofluores¬
cence such a tumor-associated antigen in Hodgkin’s disease
tissue, not present in adjacent normal tissue

(75,

77).

Also, using immunoelectrophoresis they were able to demon¬
strate two antigens common to 18 of 19 Hodgkin's disease
spleens,

two of four suspicious spleens, and four of seven

pathologically negative spleens,
tion in the positive spleens

but in increased concentra¬

(75).

This further piece of

evidence suggested to them a hypothesis which they proposed
for the pathogenesis of Hodgkin's disease

(76).

In it,

host T cells are infected by a virus leading to a changed

.
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suface antigen (26)

- perhaps the tumor associated antigen

which they have found.

If the transformed cell also

manages to maintain host tolerance, a graft versus host
reaction might ensue, leading first to lymphocyte reaction
and,

in time,

to lymphocyte depletion with repopulation by

plasma cells and proliferating reticulum cells and their
end stage Reed-Sternberg cells.

Because of T cell involve¬

ment in the graft versus host reaction,

there would be

systemic anergy, a condition frequently associated with
active Hodgkin’s disease

(1).

If their hypothesis is correct,

then a further con¬

sequence would be that in the presence of an ongoing cell
mediated immune reaction,

such as the graft versus host

reaction proposed here, at least for the early part of the
pathogenesis,

there would be T cell blast transformation

and lymphokine production.

If one of these lymphokines is

a factor which activates cells competent to produce
endogenous pyrogen to do so, as proposed by Atkins

(7)»

then we might expect to demonstrate such a lymphokine in
lymphoid tissue from patients with Hodgkin’s disease.
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OBJECTIVES

The objective of the research discussed below is

to

investigate the release of pyrogen in vitro by cells from
patients with Hodgkin's disease.

The three separate aims

of the three studies which make up this work are outlined
below,

I.

based on information discussed in the introduction.

Comparison of spontaneous pyrogen release in vitro by

lymphoid tissue from patients with Hodgkin's disease with
that by lymphoid tissue from patients without Hodgkin's
disease.
As noted,

endogenous pyrogen release is a well estab¬

lished pathway in the mechanism of fever production in a
number of experimental models, but evidence for this path¬
way in clinical fever is scanty

(4).

Second, fever commonly

accompanies Hodgkin's disease in the absence of demonstrable
infection (65).

Third, EP release in vitro has been demon¬

strated for cells from another tumor commonly associated
with fever - renal cell carcinoma, and a
found in the tissue of this tumor (15,

pyrogen has been

82).

Finally, EP

release in vitro has been demonstrated for lymphoid tissue
from patients with malignant lymphomas
In view of this,

(16).

the first objective of these experiments

is to compare EP release in vitro by cells from lymphoid

.

.
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tissue of patients with Hodgkin's disease with that by
cells from lymphoid tissue of patients with other disorders.

II.

Investigation of the effect of serum on pyrogen release

by lymphoid tissue in vitro.
The lack of correlation between demonstrable pyrogen
release by tissues in vitro and the presence of clinical
fever in the patient has

been noted above

(15*

16).

One

explanation for this is that the cells have not been acti¬
vated in vivo to releaa €EP.

Alternatively certain factors

may be acting in vivo to suppress EP production and re¬
lease.

In order to investigate the latter possibility,

the effect of different concentrations
of sera upon in vitro EP release was examined.

III.

Studies of the action of lymphocytes on induction of

pyrogen release by blood leukocytes.
As discussed above,

Hodgkin's disease may represent a

proliferative response to a foreign antigen or to a self
antigen which has been recognized as foreign by abnormal
lymphocytes

(76,

58,

97).

Also,

sensitized lymphocytes

have been shown to release a substance, perhaps a lymphokine, which may activate normal leukocytes to produce endo¬
genous pyrogen, when these lymphocytes are themselves acti¬
vated by the sensitizing antigen (3,

7).

Release of such a
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substance by activated or altered lymphocytes in spleen
and lymph nodes from patients with Hodgkin’s disease
could explain the "spontaneous” release of pyrogen
characteristic of these tissues,

through interaction of

these immunocompetent cells with tissue polymorphonuclear
or mononuclear cells capable of endogenous pyrogen production.
To examine this hypothesis, lymphocytes from spleen and
lymph node tissue were incubated with blood leukocytes in
an attempt to induce a pyrogen release.

30

MATERIALS AND METHODS

I.

Sterile pyrogen free technique.

All materials, glassware,

and reagents used in these experiments were sterile and pyrogen
free.

Metalware, glassware, and glass wood were sterilized in

hot air ovens at l8o° C for 2 hours.
at 15 p.s.i.

for 90 minutes.

Solutions were autoclaved

Alicuots were incubated in

thioglycollate broth and tested for pyrogenicity in rabbits.
Reagents not prepared in this laboratory were pyrogen tested
before use, or were obtained sterile and pyrogen free.

II.

Reagents.

Tissue culture medium (TCM).

Auto POW Eagle

minimal essential medium (Flow Laboratories, Rockville,
Maryland) was prepared as follows:

9-39 grams Auto POW

medium was made to one liter with sterile water.

The

solution was autoclaved 20 minutes at 15 p.s.i. pH was
adjusted to 7.4

by the addition of sodium bicarbonate

solution, and penicillin-streptomycin (Grand Island
Biological,

Grand Island, N.Y.) was added to 5 units

penicillin and 5 micrograms streptomycin per ml. of tissue
culture medium.

Just before use, heparin (Liquemin Sodium,

Organon, W. Orange,

New Jersey) was added to tissue culture

medium to a final concentration of 10 units per ml.

Modified Krebs-Ringer-Phosphate buffer (KRP buffer).
Na2HP0i| solution was filtered and adjusted to
A base prepared of 40 ml. of 1.15% KC1,

A 1.43%

jH 7.4 with HC1.

6ml. of 1.22$ CaC^ and
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2 ml.

3*82$ MgSOh

7H2O in sufficient saline to bring the total

volume to one liter was autoclaved for 90 minutes.

105 parts

base and 20 parts phosphate solution and 10 units/lml. heparin
were combined just before use.

Human serum albumin.

A 25% salt poor albumin solution

(American National Red Cross) was added to TCM or to KRP
buffer as described below,

for the isolation of lympho¬

cytes by the column procedure.
Heat killed Staphylococcus albus.
maintained on agar.

A

strain of S.

albus was

Cells from an 18 hour broth culture of

the bacteria were washed with saline, resuspended in saline
and autoclaved for 20 minutes.

They were stored at -18°C
Q

in a suspension of approximately 5x10

bacterial cells/ml.

estimated by comparison of optical density with a standard
curve.

III.

Pyrogen Assay.

Pyrogen testing was carried out in

adult New Zealand White rabbits
North Haven, Conn.).

(Montowese Rabbit Farms,

Animals were boxed for nine hour

intervals in a constant temperature room (l8.3°C) and
termperatures were measured at 15 minute intervals with
Telethermometer

(Yellow Springs Instrument Co., Yellow

Springs, Ohio) or continuously with automatic temperature
recording equipment

(Rustrak Gulton Industries, Manchester,

New Hampshire) via rectal thermoprobe.

Rabbits were not
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used if a stable baseline temperature was not present
for 30 minutes prior to each injection.

Each rabbit was

used for only 5 consecutive calendar days to prevent inter¬
ference with the assay due to hypersensitivity to human
serum constituents.
"Dose"

(see below) refers to the number of cells

incubated in the supernate to be assayed.
be assayed were injected via the ear vein.

Supernates

to

In most experi¬

ments the same rabbits received both control and experimental
supernates, and the same supernate was injected into more
than one rabbit, whenever sufficient material was available.
The maximum temperature elevation occurring between 30
and 75 minutes after injection was charted.

IV.

Preparation of tissues.

Spleens and lymph nodes were

obtained in saline directly from the sterile field at
operation.

The tissues were weighed,

then minced in

tissue culture medium, and the spleens additionally screened
through wire mesh.

The suspensions were cultured in

thioglycollate broth, a free cell count was determined
by coulter electronic particle counter

(Coulter Electronics,

Hialeah, Fla.) and a cover glass smear was made to be
stained with Wright’s stain for differential count.

V.

Preparation of normal leukocytes.

Venous blood was

withdrawn into a heparinized (lOu/ml) syringe from normal

,
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volunteers, or,

in some cases from patients.

It was allowed

to sediment for one hour, after which time the leukocyte
rich plasma was removed and centrifuged at 500g for 15
minutes.
lOu/ml)

The cells were resuspended in TCM (with heparin
counted by means of a coulter particle counter,

and added to the incubation flasks to provide 3-7x10
per white cell dose.

7

cells

A cover slip slide differential was

performed from blood smears after staining with Wright’s
stain.

VI.

Column separation of lymphocytes.

columns

Size #20 glass

(Kontes Glass Co., Vineland, N.J.) were filled with

glasswool under saline using sterile techniques.
eluate saline was cultured.

The

A solution of modified Krebs-

Ringer-Phosphates buffer containing heparin (lOu/ml) and
human serum albumin (0.75-1.5$) was run onto the column
and was allowed to equilibrate at 37°C.
A portion of the spleen cell suspension was strained
through several layers of sterile gauze and the concentration
adjusted to approximately 2x10

7

cells per ml.

in TCM with

lOu/ml. heparin and 1.5$ human serum albumin.
The spleen cell suspension was run onto the column
rapidly, allowed to stand 30-40 minutes at 37°C, and eluted
with twice the volume of KRP buffer containing heparin and
albumin.

The eluate was centrifuged at 500g for 15 minutes,

and the cell button resuspended in tissue culture medium
to be added to the incubation flasks at approximately 2x10

g

.
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cells per dose of lymphocytes.

An aliquot was cultured

and a Wright's stained cover slip smear was made for
differential count.

VII.
A.

Incubations.
Incubation for spontaneous pyrogen release.

suspensions were incubated to provide 0.5-1.8 g.
wet weight
node

(1.3-7.0x10^ free cells) or 50-333 mg.

(wet weight),

per dose.

4-5 ml TCM with 10-15# serum,

spleen,
lymph

Each dose was suspended in
in an Erlenmeyer flask. The

flasks were flushed with 5# CO2 in air
Products),

Tissue cell

(Matheson Gas

sealed with Parafilm over a cotton plug, and

incubated overnight in a Dubnoff shaker at 37°C.

They

were resuspended after 24 hours, and in some cases,
hours,

as follows.
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The contents of the flasks were

centrifuged at 600 g for 15 minutes and the supernatants
saved.

The cell clump was resuspended and reincubated

as on the first day.

The supernatant of the first cen¬

trifugation was then recentrifuged at 2000g for 30 minutes,
and the supernate of this spin was stored at 4°c for 1-7 days
or at -l8°C for 1-3 weeks until it could be tested for
pyrogenic activity.
B.

Activation with Staphylococci.

One flask was usually

prepared as above with 0.5 ml. heat-killed S. albus added
per dose.
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C.

Serum Studies.

Suspensions were made up as above

except that serum concentration was varied between

10-15#

and 30-35# with patient and/or normal 0- homologous

serum.
D.

Activation by lymphocytes.

Spleen.

Incubations

with lymphocyte preparations were done using the cells
eluted from the column as described.

Incubation sus¬

pensions were made up as above with 10-15# serum in TCM

Q
to a total volume of 4-5 ml. per injected dose.

1-2x10

column cells were incubated alone as one lymphocyte
dose, or with two leukocyte doses

(at 3-5x10? WBC/dose).

In some cases the leukocytes were added to the lymphocyte
suspension at the outset,

in others after lymphocytes

had incubated alone for 24 hours.
Lymph node.

One lymph node does

(50-250 mg.) was used

in place of spleen column lymphocytes.
procedure was the same.

Otherwise the

.

,
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RESULTS

IA.

Spontaneous endogenous pyrogen release by splenic
tissue in vitro.
Thirteen spleen specimens from patients with

Hodgkin’s disease

(HD) and twelve from patients with

diseases other than Hodgkin’s disease
disease,

NHD) were processed.

The

(non-Hodgkin’s

patients in the

NHD group included six with idiopathic thrombocytopenic
purpura

(ITP),

three with non-Hodgkin’s lymphoma

(NHL),

one with autoimmune thrombocytopenia secondary to systemic
lupus erythematosus, one with a splenic artery aneurysm,
and one with a traumatic ruptured spleen.
The specimens were prepared and incubated as described
in the Materials and Methods section.

Briefly,

the cells

were suspended in tissue culture medium (TCM) with 10-15#
serum and resuspended after 24 hours for a second 24 hours.
Supernates from each incubation were tested for pyrogen
by injection into rabbits.

An example of a typical fever

curve obtained is shown in Figure I.

This has the

characteristic short latency, early peak (

{

90 minutes),

and rapid fall to normal characteristic of EP fever.

For

each injection, peak termperature elevation occurring
within 90 minutes was determined.

Since the relation between

pyrogen dose and temperature elevation is approximately

,

„
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linear up to 0.8° C. elevation (84),

the mean peak tempera¬

ture elevation for any group of supernates was considered
the measure of pyrogen for that group.
The results of comparison of pyrogen release by
spleen cells from patients with various diseases is shown
in Figure II.

The mean peak temperature elevation produced

by supernates from the first 24 hour incubation is 0.40±.04°
C for the HD group,

0.13*.02° C for the NHL group,

0.20^.04°

C for the ITP plus lupus group, and 0.39*.10° C for the
other two.

While results from the HD group and the last,

and presumably most normal spleen group are similar,

the

last group is heavily weighted by the pyrogen production
by cells from the ruptured spleen.

This patient had been

observed for two days properatively, and clinically demon¬
strated inflammation.

Over all, comparing the HD group

with the entire NHD group
difference

(Fig.

3)s

there is a significant

(p £ .02 by t test for difference of means)

be¬

tween the amount of pyrogen released during a first incuba¬
tion from tissues in the two groups.
To look at this in a different way,

the mean peak

temperature elevation produced by injection of the supernate from the first incubation, was examined for each spleen;
when the mean elevation was greater than 0.3° C,
was considered "positive" for pyrogen release.

the tissue
Nine of the
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thirteen spleens in the HD group were positive, and only
three of twelve in the NHD group were positive.

The

number of cells and weight of tissue per dose are not
significantly different in the two groups

(Table I).

Similarly the response to a phagocytic stimulus was not
different,

as all specimens in each group produced pyrogen

in response to incubation with heat-killed staphylococci.
Differential counts were performed on a suspension
from each spleen, and the percentage of pyrogen producing
cells-polymorphonuclear leukocytes,
monocytic cells-was compared.

eosinophils, and large

There were 27-2% of these

cells in the suspensions from the HD group, and 25-2$ in
the suspensions from the NHD group.

Thus

there is no sig¬

nificant difference between the two groups with respect to
the proportion of pyrogen producing cells.
The results of assay of spontaneous pyrogen release
during the second
III.

24 hours is also shown in Figures II and

Pyrogen release was greater in all groups during the

second period than during the first.

The difference in

pyrogen production between the HD group and the NHD group
during this incubation is not significant.

This result

suggests that there has been a ’’warming up”

to pyrogen re¬

lease, a process in which the spleen cell suspensions from
the HD patients had,

for some reason, a head start.

It
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may also indicate a greater capacity for release, since
the total production is therefore, greater in the HD
group.
In the previous series of Bodel,

spontaneous pyrogen

release by spleen cells did not correlate with histological
evidence of pathological involvement of the tissue.

In

this series only 20$ of the spleens from patients with HD
are positive for disease as determined by the surgical
pathologist.

This number is not large enough to allow

division of the H D group into two subgroups
and one without,

(one with,

clear-cut pathological involvement)

for further analysis.

.

.

Figure Is

Typical Fever Curve.

The temperature response in one rabbit to injection

8
(at arrow) of supernate from incubation of one dose
cells)

of spleen cells from a patient with Hodgkin's

disease.

The peak temperature elevation is 0.55° 0.

(3»5 x 10

40.00

Time

Figure I

(minutes)

_#*
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Figure II:

Spontaneous Pyrogen Release by Spleen Cells
in vitro:

I.

In this and subsequent figures,
peak temperature elevations,

bars represent mean

- standard error of the mean,

produced by injection of supernate from the incubation of
tissue cells.
supernate,

In experiments with spleen,

injected into a single rabbit, was derived from

an average of 3.5 x 10
nodes,

each dose of

8

cells;

in experiements with lymph

from an average of 170 mg.

node tissue.

(wet weight) of lymph

The numbers in parentheses refer to the

number of supernate doses assayed in each group.
following abbreviations are used:
Hodgkin’s disease;
Hodgkin’s lymphoma;

NHL,

HD,

The

tissue from patients with

tissue from patients with non-

ITP,

tissue from patients with idio¬

pathic thrombocytopenic purpura;

SLE,

with systemic lupus erythematosus.
first 24 hour incubation.

Day 2,

tissue from patients

Day 1 refers to the

to the second.

In this

figure ’’other” refers to one tissue from a patient with
traumatic ruptured spleen and one from a patient with a
splenic artery aneurysm.

Pyrogen release is presented

for Day 1 and Day 2 incubations for the four different groups
of spleen tissues.

Temperature Elevation °C
o

H*

Figure II

Figure III*

Spontaneous Pyrogen Release by Spleen Cells
in vitro •.

In this and

II.

subsequent figures,

NHD refers to tissue

from patients with diseases other than Hodgkin’s disease.
In comparisons only differences significant to p <
by t test for means are noted.

In this figure,

0.2

mean peak

temperature elevations following injection of supernates
are compared for HD and NHD groups of tissues,
a first and second

incubation.

during both

Day 1

Temperature Elevation

o

p <.02

0.5

HD

NHD

Figure III

ED

NHD
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Table

I : Comparison of spleen cell populations between
HD end NHD groups*

HD

■ Wet weight(g)
per dose
Free cells(xlO^)
per dose
Non-lynxohocyte
cells~(/S)

NHD

1.04±.07

1.01-.06

3.52-.70

3.57^.36

2.7±2

25-2
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IB.

Spontaneous endogenous pyrogen release by lymph node
tissue in vitro.
Nodes were obtained from four patients with Hodgkin’s

disease,

three patients with non-Hodgkin’s lymphoma,

three

patients with metastatic carcinoma, and five with adeno¬
pathy with a reactive histology.

This latter group

included pathological diagnoses of lymphoid hyperplasia,
sinus histiocytosis, and in one case,

caseating granuloma

consistent with lymphogranuloma venereum.

The tissues were

minced, and the cells incubated in TCM containing 10 or
30# serum for successive 24 hour periods, as described in
Materials and Methods.

Supernatants were injected into

rabbits to determine the presence of endogenous pyrogen.
The results of pyrogen testing are shown in Figure IV.
Clearly, only small amounts of pyrogen were released by
cells from any of the groups, during a first or second
incubation.

The small release may be due to inadequate

amounts of tissue per dose used in this system.

The diffi¬

culty in obtaining larger lymph node specimens made this
dose a necessity.

There is no significant difference

between pyrogen release by HD tissue compared with that by
NHD tissue

(Fig. V).

Neither is there any significant

difference between the two groups with respect to average
amount of tissue per dose,

being 171-41 mg# in the HD

14

8

group, and 173-21 in the NHD group.

Estimates of cell

types from differential smears were very difficult to
perform in these experiments,
unusually fragile.

However,

because the cells appeared
the smears appeared com¬

parable between the two groups.

In only one case

(a

carcinoma node) were there more than 5% polymorphonuclear
leukocytes in a smear.

Figure IV:

Spontaneous Pyrogen Release by Lymph Node
Cells in vitro:

I.

Pyrogen release is presented for Day 1 and Day 2 in¬
cubations for the four different groups of lymph node
tissues.

Reactive refers to lymph node tissue displaying

a reactive histology

(see text),

with metastatic carcinoma.

Ca to tissue from patient
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Figure Vi

Spontaneous Pyrogen Release by Lymph Node
Cells in vitro t

II.

Mean peak temperature elevation following injection
of supemates from incubations of lymph node from pa¬
tients with Hodgkin's disease is compared with that from
patients with other diseases.

Data for both a first and

second 24 hour incubation are shown.
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IIA.

Serum studies:

the effect of varied serum

concentration upon spontaneous EP release
by lymphoid tissue in vitro.

Since,

in Bodel’s work, spontaneous endogenous

pyrogen release has not been correlated with fever in the
patient,

it is possible that factors acting in vivo may

modify the capacity of these cells for EP release.
of these factors may be a serum inhibitor.
tions in Bodel’s series,

One

In the incuba¬

the serum concentration in the

incubation mixture was 10-15$.

In order to investigate

the possible effect of higher serum concentration on in
vitro EP release,

cells from lymph nodes and spleens were

incubated in TCM with 10-15$ serum and 30-35$ serum.
Serum was either autologous or homologous,
0- donor,

but for each individual specimen,

serum was used at both concentrations.

from a normal
the same

Incubation was

carried out for two successive 24 hour periods.
Because of the small number of nodes

(4)

in this

study, and the lack of significant difference between
pyrogen release by the nodes during a first or second
incubation (Fig.

IV), pyrogenic responses to supernates

from incubation on day one and day two were combined in
determining an average.

Therefore, Figure VI shows mean

peak temperature elevations for HD and NHD tissues for both days.

*
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Lymph node cells from Hodgkin’s disease patients
made less pyrogen when incubated with 30$ serum than when
incubated with 10$ serum.

However,

small number of supernates assayed,
is not statistically significant
apparent,

because of the
this apparent difference

(p ^ .2).

There is no

nor significant, difference between the serum

concentrations in their effect on pyrogen release by
NHD tissue.
The same study was performed with 11 samples of
spleen tissue

(Figure VII).

Results for a first incubation

alone, and for pyrogen release per incubation during two
consecutive 24 hour incubations are presented.
an apparent,

but not statistically significant

There is
(p < .2),

difference in pyrogen release during the first 24 hours
incubation by spleen cells from HD patients, when incubated
in the two concentrations of serum (Fig. Vila).

Cells

incubated in 30$ serum released less pyrogen than those
incubated in 10$ serum.

There is no apparent effect of

incubation in 30$ serum as compared with 10$ serum on pyrogen
release by the NHD spleen cells.
When pyrogen release, per incubation,
two incubations is examined,

(Fig. Vllb),

averaged over

there is no

significant difference evident between the effects of the two

.

.
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serum concentrations on pyrogen release by spleen cells
from either HD or NHD patients.
Since it was felt that autologous serum might be
more effective than homologous serum in suppressing
pyrogen release from HD tissues, a subseries

(six

specimens) was selected in which only those spleens
which had incubated in both high and low concentrations
of autologous serum were included (Figure VTIc, d).

Again

there is an apparent but not significant (p<.2) difference
in pyrogen release during a first incubation when cells
from HD spleens were incubated in 30% as compared to 10%
serum.

There is no significant effect of varying serum

concentration demonstrated in .the NHD group for the
first incubation nor in either group if the pyrogen released
on each of two incubations is averaged over both incubations.

Figure Vis

Effect of Serum Concentration on Pyrogen
Release by Lymph Node Cells in vitro.

Comparison of mean peak temperature elevations
following injection of supernates from incubation of
lymph node tissue in either 10% or 30% serum,
first or second 24 hour incubation.
and NHD groups are shown.
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Figure Vila:

Effect of Serum Concentration on Pyrogen
Release by Spleen Cells in vitro s

I.

Comparison of mean peak temperature elevations
following injection of supernates from incubation of
spleen cells in either 10fo or 30^ serum,
incubation.

during the first

Data for both HD and NHD groups are shown.
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Effect of Serum Concentration on Pyrogen
Release by Spleen Cells bn vitro;

II.

Comparison of mean peak, temperature elevations following
injection of supernates,
in either 10$ or

30$ serum during either a first or second

24 hour incubation.
NHD groups.

from incubation of spleen cells

Data are presented for both HD and

T emp eratur e Elevation

o

Figure VIlb

Figure Vile*

Effect of Serum Concentration on Pyrogen
Release by Spleen Cells in vitroa

III,

Comparison of mean peak temperature elevations folio
ing injection of supernotes from incubation of spleen
cells in either 10% or 2,0% autologous serum during a
first incubation*
NKD groups.

Data are presented for both HD and.

o
Temperature Elevation
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Figure Vlld*

Effect of Serum Concentration on Pyrogen
Release by Spleen Cells .in vitro:

IV.

Comparison of mean peak temperature elevations
following injection of supernates from incubation of
spleen cells in either 10$ or

autologous serum,

during either a first or second 2b hour incubation,
are presented for both HD and NHD groups.
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IIB.

Serum Studies:

the effect of varied serum source

upon spontaneous EP release by lymphoid tissue in
vitro.

In order to further investigate the possibility
that a factor in the serum of Hodgkin's disease patients
may suppress pyrogen production,

and thus, perhaps,

be

responsible for preventing EP release in vivo, aliquots
of cells from a single tissue were incubated in autologous
serum, or in homologous normal 0- donor serum.

Concentra¬

tions of 10-15$ or 30-35$ serum in TCM were both used,
but in each autologous-homologous pair of incubations,

the

same concentration was employed.
Again, all incubations for each tissue over two days
were combined in determining the average pyrogen released
during each incubation of the seven lymph node specimens
(Figure VIII).

HD lymph node cells incubated with auto¬

logous serum released significantly less pyrogen per 24
hours of incubation,

than did the same tissue incubated

with homologous normal serum (p < .05).

There is no

significant difference between pyrogen release by lymph
node cells in the NHD group when incubated with the two
types of serum (p < .2).
In similar experiments with spleen cells from 16

.

.
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specimens, varying the type of serum did not alter
release of pyrogen during the first 24 hour incubation
(Figure IXa) or release, per incubation, averaged over
two consecutive 24 hour incubations
as noted in Figure Vila,

(Figure IXb).

Since,

30$ serum appears to suppress

release of pyrogen by spleen cells in the HD group,
during the first 24 hours,

an effect of autologous vs.

homologous serum might be more marked in a group of tissues
incubated at this concentration.

Consequently results of

eleven experiments in which splsen cells from either HD
or NHD patients had been incubated in both 30$ autologous
and 30$ homologous normal serum during the first 24 hour
incubation were analyzed
patients with HD,

(Figure IXc).

Spleen cells from

but not from patients in the NHD group,

produced less pyrogen when incubated with 30$ autologous
as compared to normal homologous serum, although the
difference is not statistically significant

(p K.

.1).

To look at these experimental results in a different
way,

comparison was made for each spleen cell preparation,

between response to supernatant from incubation in 3Q$-autologous serum and in 30$ homologous normal serum, during the
same period.

If the mean peak temperature elevations dif¬

fered by greater than 0.15° C,
real.

the difference was presumed

If the difference was less than 0.15° C,

the responses

,

.
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were considered equal.

In experiments with six spleens

from patients with HD, six comparisons could be made.
In four,

the incubation in homologous normal serum

released more pyrogen;

in two the responses were equal.

In experiments with five spleens from NHD patients
ZITP, 1 SLE)

five comparisons could be made.

(2NHL,

In two

cases more pyrogen was released by incubation in homo¬
logous serum;
serum.

in one case by incubation in autologous

In two cases no difference was found.

Figure VIII*

Effect of Serum Source on Pyrogen Release
by Lymph Node Cells in vitro.

Comparison of mean peak temperature elevations fol¬
lowing injection of supernates from incubation of lymph
node cells in either autologous
logous

(Homo)

serum,

hour incubation.
groups.

(Auto) or normal homo¬

during either a first or second 24

Data are presented, for both HD and NHD

Figure VIII

Temperature Elevation

Figure IXa:

Effect of Serum Source on Pyrogen Release
by Spleen Cells in vitroi

I.

Comparison of mean peak temperature elevations fol¬
lowing injection of supernates from incubation of spleen
cells in either autologous or normal homologous serum,
during a first incubation.
HD and NHD groups.

Data are presented for both
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0°

HD

MID

mm

I

(28)

(25)

Auto

Homo

Figure IXa

(9)

(9)

Auto Homo

Id

Figure* JXb*

Effect of Serum Source on Pyrogen Release
by Spleen Cells in vitro:

II.

Comparison of mean peak temperature elevations
following injection of supernates from incubation of
spleen cells in either autologous or normal homologous
serum,

during either a first or a second 24 hour incuba¬

tion.

Data are presented for both HD and NHD groups.
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Effect of Serum Source on Pyrogen Release
by Spleen Cells in vitroi

III.

Comparison of mean peak temperature elevations fol¬
lowing injection of supernates from incubation of spleen
cells in either
serum,

autologous or JOfo normal homologous

during a first 24 hour incubation.

sented for both HD and NHD groups.
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III.

Endogenous pyrogen release in vitro by a combined
population of tissue lymphocytes and circulating
blood leukocytes.

In order to examine the effect of lymphocytes from
these tissues on induction of pyrogen release by cells
capable of pyrogen release,
state,

but obtained in an inactive

tissue lymphocytes were incubated together with

blood leukocytes.
Since the available lymph node tissue was small in
amount, and since its composition was, in all cases but one,
under five per cent polymorphonuclear leukoyctes,

it was

decided to use lymph node cells obtained directly from
teased or minced lymph nodes as a lymphocyte source.

To

obtain spleen lymphocytes, a glass wool column was used,

to

which the phagocytic cells were allowed to stick (see
Materials and Methods).
small lymphocytes

The eluate cells were predominantly

(average of

89$ in 17 experiments).

The

majority of the remaining 11% were large mononuclear cells,
some of which may have been large lymphocytes rather than
tissue monocytes, and,

therefore, non-pyrogen producing.

Lymph node cells and spleen column eluate cells were
then incubated with blood leukocytes
from patients.

from normal donors or

Control suspensions of tissue lymphocytes

alone, and of blood leukocytes, alone, were also incubated.

.

.

.

78

Supernates obtained after successive 24 hour incubations
were assayed for pyrogen.

A "positive" response required

that the supernate from the incubation of the two cell
populations together contain sufficient pyrogen to produce
a mean peak temperature elevation greater than 0.3° C and
greater than the mean peak temperature elevations of each
of the control populations summed.

When a supernate from

an incubation containing either tissue lymphocytes or blood
leukocytes alone produced sufficient pyrogen to produce a
mean peak temperature elevation greater than 0.3° C,

that

experiment was excluded from the series, since induction of
pyrogen release could not be determined in that case.
The results of the experiments with lymphocytes from
spleen are

presented in Table II.

patients were used,
experiments.
group,

Whe«i spleens from HD

there were four positives in seven

When the spleens were from patients in the NHD

there was only one positive of 10.

This single posi¬

tive occurred with cells from the spleen that had ruptured
two days preoperatively.

The difference between the results

in the two groups is significantly different by chi square
(p

K .05).

There is no significant difference in the numbers

of cells other than small lymphocytes between the two groups.
The observation that there is a significant difference
between the activity of the two populations of lymphocytes
suggests that th tblood leukocytes were not responding to a

.

,
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non-specific stimulus in these incubations.

This

possibility was further explored by incubating normal
blood leukocytes with eluate from the column in the
absence of spleen cells;

no pyrogen release occurred.

To

further assure that the lymphocyte suspensions were not
the source of the pyrogen, seven experiments were performed
O

in which 1 x 10° cells from the column were incubated with
staphylococci,

to provide a phagocytic stimulus,

no case did pyrogen release occur.

Furthermore,

and in
a positive

response was never obtained by injection of the supernate
from the control incubation of the column lymphocytes alone.
When lymph node lymphocytes were studies in this system
(Table III)

there were three "positives" and no negatives

in experiments using lymph nodes from patients with Hodg¬
kin's disease.

There were only 3 positives out of nine

experiments using lymph nodes from patients in the other
groups

(two of four positive in the NHL group, one of one

in the reactive group,

none of four positive in the meta¬

static carcinoma group).

The difference between the results

in the HD and NHD groups is significant by chi square.
(p

K

0.02).

There is no significant difference between the

two groups with respect to percentage of cells other than
small lymphocytes amongst the lymph node cells
with 24±l8$).

(14±6% compared

Two experiments were excluded, one each from

the HD and NHL groups,

because the lymph node cells produced

.

»
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sufficient pyrogen, incubated alone, at the dosage
used for incubation with blood leukocytes,

to inter¬

fere with the interpretation of results from the
combined incubation.

,

Xable II:Pyrogen release in incubation mixtures
containing spleen lymphocytes and
blood 1eukocyt e s.

Pyrogen Release

Positive

HD

4

NED

1

Negative

9

Total
Experiments

Percent
Positive

?

57

10

10

p<.05 by chi square

* Mean peak temperature elevation >0*3°C. See text for
explanation.

Table III: Pyrogen release in incubation mixtures
containing lymph node cells and
blood leukocytes1.

Pyrogen Release

Positive ,<r

Negative

Total
Experiments

,

Percent
Positive

HD

3

0

3

100

HKD

3

6

9

33

p<.02 by chi square

* Mean peak temperature elevation>0.3°C. See text for
expl ©nation®
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DISCUSSION
These results,
Bodel

(15,

16)

like those of the earlier series of

show that spleen tissue from patients with

Hodgkin’s disease releases pyrogen spontaneously in vitro,
and that this
hours.

pyrogen release continues for at least 48

When assayed in rabbits,

the pyrogen behaves,

an endogenous pyrogen rather than endotoxin,
a prompt,

like

since it causes

early fever with onset within fifteen minutes and

peak temperature elevation within 90 minutes.

Also,

repeated injections of tissue pyrogen three times per day for
four days,

continues to cause undiminished pyrogenic responses.

Spleen cells from patients with Hodgkin’s disease
release significantly more pyrogen during a first 24 hour
incubation than do spleen cells from patients with other
conditions requiring splenectomy,
lymphoma.

including non-Hodgkin’s

By the second day, pyrogen release between the

two groups is comparable.
Because pyrogen release continues for two days in
vitro, and increases in amount over that period,

it is

likely that the pyrogen releasing cells are spleen mono¬
cytes.

Polymorphonuclear leukocytes, unlike monocytes,

release pyrogen only 12-16 hours after a single activating
stimulus

(17).

However,

release from this

it is possible that pyrogen

tissue may be effected by successive

,

.
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activation of populations of polymorphonuclear leukocytes,
each population active for only 12-16 hours.
It is unclear exactly what spontaneous endogenous
pyrogen release in vitro represents,

especially since

pyrogen release by all groups of tissue was similar after
24 hours.

It may indicate a previously altered state of

the cells or it may result from non-specific activation by
some process in the surgical or laboratory handling of the
tissue.

Clearly,

if it is the latter,

then there is some

difference in the response of the HD and NHD groups to this
activation stimulus.

This difference could be one of acti¬

vation threshold, degree of res pnse to identical stimuli,
or speed of response.
state of the cell,
pyrogen release,
its effect,

If it represents a previously altered

that alteration may be actual in vivo

there must be some in vivo modification of

since none of the patients in the HD group were

febrile at the time of, or shortly prior to surgery.

This

modification might result from EP inactivation in the circu¬
lation (such as by protein binding or enzymatic degradation),
prevention of EP effect upon the thermoregulatory neurons
of the hypothalmus, or prevention of fever by interruption
of the efferent limb of the termperature regulating mechanism,
such as by altered function of the autonomic nervous system.
The observed spontaneous EP release may also result
from the combined effect of nonspecific activation and a

•

.
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disease-specific difference in cell behavior between the
two groups of tissues.

For instance, release of pyrogen

after the first 24 hours may be due to nonspecific activation,
whereas the early response,

seen in tissues of the HD group,

may be due to a specific activating condition present in
the one,

but not the other group.

The similar early

release of EP from the spleen tissue of the patient with
traumatic rupture and inflammation, a situation that seems
likely to have led to in vivo cell activation,

supports

this conclusion.
Only 20% of the spleens from the HD group were "positive"
for evidence of the disease on histological examination.
This group was too small to allow division of the HD group
into two subgroups
involvement)

(one with, and one without pathological

for analysis.

Previous work by Bodel, however,

has shown no correlation between in vitro pyrogen release
and histological involvement

(16).

This suggests that if

the observed pyrogen release is, at least in part, disease
specific,

it either does not require

pathological involve¬

ment of the tissue by the disease process, or it occurs
in the tissue without leaving the histological evidence
which we recognize as Hodgkin's disease.

An example that

such alterations take place is the demonstration of a HD
associated antigen in pathologically "negative" spleens from
patients

with the disease

(75) •

-
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The results of these experiments,
in Hodgkin’s disease,

then,suggest that,

there may be a relation between altered

production of EP in vitro and a high frequency of fever iji vivo.
In a general way,

they support the hypothesis that EP

release from lymphoid tissue might be the mechanism for the
fever of Hodgkin’s disease.

However,

they do not explain

the activation mechanism for EP release in patients with
Hodgkin's disease.
Unlike the results in Bodel's series

(16),

there is

no evidence here that lymph node tissue from patients with
Hodgkin’s disease releases significantly more :pyrogen upon
in vitro incubation than does nodal tissue from patients
with other conditions requiring lymph node biopsy.

This

suggests that the lymph node is not a major site of pyrogenproducing cells in this disease.

Further evidence for this

conclusion is the finding that the pyrogen content of the
supernates incubated with lymph node cells from two patients
with febrile histories is not significantly different from
that of supernates in the group as a whole

(mean peak temp¬

erature elevation of 0.20° C compared with 0.29° C).

This

does not exclude a role for lymph node cells in the process
of pyrogen production as activators of other cells.

It

probably does indicate that few cells capable of pyrogen
production are present in the nodes.

However, because the

results of the serum studies, discussed below,

show decreased

.

.
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pyrogen release when lymph node cells from HD patients are
incubated in autologous serum and in 30# serum,
for EP release may have been masked,

the capacity

in this series,

by the

use of both autologous serum and 30% concentration in some
incubations.
Studies of the effect of serum on pyrogen release
were undertaken to look for factors which might modify the
capacity of tissue cells for

pyrogen release.

Such a

factor might help to explain the lack of correlation between
in vitro EP release and clinical fever, reported in Bodel's
series.

Clearly,

cells in vivo are exposed to the patient’s

serum at a concentration greater than the 10-15# used in
our routine incubations.

It was hypothesized that a factor

might be

present in the patient’s serum which at most times

prevents

the cells’

manifest in vivo.

capacity for EP release from becoming
Failure of this suppressive mechanism

might then lead to a state of fever.
Two studies were set up, one in which serum concentra¬
tion was either 10 or 30#, and the other in which the serum
used was either autologous or normal homologous.

In each

study an effect of changes in serum was more apparent when
lymph node, rather than spleen,
be because their lesser
hibited.

Alternatively,

tissue was used.

This may

pyrogen release is more easily in¬
it may be that only pyrogen release

by mononuclear cells is inhibited by a serum factor, and
spleen pyrogen release may be due to pyrogen production by

.

.
.

.
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both mononuclear and polymorphonuclear cells.
results,

in both tissues,

consistently support the conclusion

that incubation in 30% serum concentration,
serum,

However the

or autologous

leads to less pyrogen release by cells from Hodgkin's

disease patients,

as compared with incubation in 10% serum

or with normal homologous serum.

No such effect was observed

on pyrogen release by cells from nodes or spleen of patients
with non-Hodgkin's diseases.

This finding suggests that the

observed suppressive effect on tissue from HD patients is
a disease-specific one.
Because the number of specimens is small and the
differences are not all statistically significant,

further

studies will be required to establish this finding con¬
clusively.

Howearer,

outlined above,

these results fit with the hypothesis,

that a factor present in the serum of

patients with HD suppresses pyrogen release by spleen and
lymph node cells from these patients.

Such a factor

would be another example of host response to his tumor,
others of which include blocking factor in malignant melanoma
and an anti-blast transformation factor
disease

(86).

in Hodgkin's

Perhaps if the series could be extended,

the

results would become significant, or in the case of the
serum concentration study, if even higher concentrations
of serum were used,

the effect might become more clear cut.

The results are encouraging and suggest that further experi¬
ments should be done.

.

.
.
,

.

,

■

89

It is not clear however,
were varied,

why,

when serum concentrations

the suppressive effect of the higher serum

concentration on s jLeen cells from patients with HD is not
maintained when the results of incubation during each 24
hour period are considered together.

This may reflect a

difference in the means by which th € HD spleen cells are being
activated on the two days.

As discussed above, spontaneous

pyrogen release by the spleen cells may be partially in
response to non-specific activation due to handling, and
partly in response to disease-specific activating mechanisms.
The serum factor may have an effect only on the diseasespecific mechanism, presumed to be acting during the first
day,

and not on non-specific activation.
If the demonstration of spontaneous endogenous pyrogen

release in vitro by spleen cells from Hodgkin’s disease
patients is not simply an artifact of handling,

we must

consider by what mechanism these cells have been altered
in vivo.
a virus,

It is possible that,

if the disease is caused by

infection with the agent may activate the cell to

pyrogen production.

Parainfluenza virus is known to cause

EP release from blood leukocytes in vitro,

for instance

(6).

Another possible etiology for Hodgkin’s disease, proposed
by Vianna, et al, suggests

that there is a virus infection

in the barrier lymph nodes of the oropharynx or gut, which
does not reach those lymph nodes which become what we recog¬
nize histologically as being involved by the disease, but

.
.
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which seeds antigen-antibody complexes to the draining
lymphoid tissue
sponse to

(98).

The disease is presumed to be a re¬

the antigen-antibody complexes.

Antigen-antibody

complexes have also been shown to be activators of EP
release in vivo and in vitro

(85).

Another possibility is that the activator in these
tissues is a lymphokine.
of Hodgkin’s disease,

In the hypothesized patogenesis

proposed by Order and Heilman,

and

discussed previously, a cell-mediated immune response occurs
in the involved tissue.

Activated T lymphocytes are now

known to produce a number of non-antibody products which
are known as lymphokines

(37).

factor, a lymphocytotoxin,
for macrophages.

These include a mitogenic

and a migration inhibiting factor

There is some recent evidence that a

lymphokine can activate blood cells to produce endogenous
pyrogen.
In our experiments,

lymphocytes from the spleens and

lymph nodes were incubated together with circulating leuko¬
cytes to look for evidence of such a substance.

In the

seven incubations in which spleen lymphocytes from patients
with Hodgkin’s disease were combined with leukocytes, pyrogen
release occurred in four instances.

Similar release occurred

in all three incubations in which lymphocytes from lymph
nodes of patients with Hodgkin’s disease were used.

Both

results are significantly different from those in which

’
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lymphocytes
were used,

from tissues of patients with other diseases
where pyrogen release occurred in only one of

ten ex jeriments using spleen cells and three of nine using
lymph node cells.
These results provide evidence for some kind of inter¬
action between the two cell populations, which results in
pyrogen release by one or both of them.
population" was about

The "lymphocyte

90$ small lymphocytes,

pyrogen producing cells;

which are non¬

these preparations incubated alone

or with a phagocytic stimulus, never released pyrogen.
Thus even the 10$ of cells which were possible pyrogen
producing cells by microscopic examination were probably
not pyrogen producing in these experiments.

Consequently,

it appears that the blood leukocytes are the source of
the measured pyrogen.

Since the same blood leukocytes did

not release pyrogen when incubated under the same conditions
without lymphocytes,

it appears that some inter-action

between the two cell populations was responsible for their
activation.
Whether the important aspect of the inter-action is
one specific to the action of lymphocytes from patients with
Hodgkin’s disease,
clear.

or a non-disease-related action is un¬

Evidence against its being non-specific is the

significant difference between the results of the experiments
using lymphocytes from tissues of patients with HD and NHD.

,
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Additional evidence against its being due to some artifact
of the column procedure, ifa experiments with spleen tissue,
such as wool particles which act as phagocytic stimuli to
the leukocytes,

is that an acellular column eluate,

incubated with blood leukocytes, does not cause pyrogen
release.

Another non-disease-specific cell inter-action

may be an immune inter-action between the two cell pop¬
ulations obtained from different individuals,

in those

cases in which the leukocytes were from a normal donor
rather than from the patient himself.
experiments with spleen cells,
experiements,

However,

both positive and negative

in both HD and NHD groups,

lymphocytes and normal leukocytes.
action, even if present,

in the

contained patient

Thus,

immune inter¬

cannot account for the difference

between the results of experiments in which patient blood
cells or normal blood cells were used.

However,

further

studies of the mixed lymphocyte reaction will be needed to
clearly resolve this question.
The evidence, at present,

favors a disease-specific ef¬

fect since induction of pyrogen release by blood leukocytes
occurs more frequently when lymphocytes from HD patients
are used.

One explanation for a specific disease-related

inter-action would be release of a lymphokine by altered
lymphocytes present in HD patients.

The results of these

experiments do not however, :pirove such a conclusion.

Further

-
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supporting evidence would be the demonstration of pyrogen
release by blood leukocytes after incubation with the
supernate of a previous incubation of the lymphocytes alone.
Whether a lymphokine is, in fact,

the mechanism for

the demonstrated lymphocyte activity on blood leukocytes,
spontaneous endogenous pyrogen release by spleen cells
from Hodgkin's disease patients in vitro may result from
the action of altered lymphocytes on tissue pyrogenproducing cells.

This alteration may be due to a reaction

to an antigen in the tissue.

A Hodgkin's disease-

associated antigen has been observed in both pathologically
diseased and apparently normal spleens from patients with
Hodgkin's disease

(75,

77).

Thus,

the findings of

altered lymphocyte function, demonstrated in this in vitro
system,

is consistent with, and would be required by,

the hypothesis for the patogenesis of Hodgkin's disease
proposed by Order and Heilman.

SUMMARY

Lymph node and spleen cells from patients with
Hodgkin’s disease and various other disorders requiring
splenectomy or lymph node biopsy were incubated in tissue
culture medium in vitro.

On the first day of incubation,

spleen cells from patients with Hodgkin's disease released
significantly more pyrogen than those from patients with
non-Hodgkin’s disease.

Pyrogen release during a second

24 hour incubation was comparable in the two groups.

There

was no significant difference between the pyrogen release
by the two groups of lymph nodes during either a first or
second

24 hour incubation.

The effect of changing serum concentration in the
incubation media from 10 to 30% was studies in this system.
Lymph node cells from patients with Hodgkin's disease in¬
cubated in 30% serum released apparently,
cantly,

but not signifi¬

less pyrogen per day than the same cells incubated

in 10% serum.

Pyrogen release by cells from patients in the

non-Hogkin’s disease group was not affected by the different
serum concentrations.
cubation,

Pyrogen release during a first in¬

by spleen cells from patients with Hodgkin’s

disease was apparently less in 30% serum than in 10% serum,
but this effect was not seen when results of both the first
and second incubations were included together.

No effect of
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serum concentration was observed on spleen cells from
patients with other diseases.
Different sera, either autologous or normal 0homologous serum, were compared for effect on pyrogen
release i_n vitro.

Lymph node cells from patients with

Hodgkin's disease incubated in autologous serum released
less pyrogen per day, over two days,

than did lymph node

cells from the same patients incubated in homologous 0serum.

The different sera did not affect pyrogen release

by lymph node cells from the non-Hodgkin's disease patients
differently.

Pyrogen release by spleen cells, whether

from Hodgkin's or non-Hodgkin's patients,

was not signi¬

ficantly different when homologous rather than autologous
serum was used.

In the experiments in which spleen cells

from patients with Hodgkin's disease were incubated in
30% autologous or 30% homologous serum, cells incubated
in autologous but not homologous serum, released apparently,
but not significantly,

less pyrogen during a first 24 hour

incubation.
In the final group of experiments,

spleen or lymph

node lymphocytes were incubated with circulating blood
leukocytes.

Four of seven mixtures released pyrogen when

lymphocytes from spleens of Hodgkin's disease patients
were used.

In only one of ten experiements was pyrogen

released when spleen lymphocytes from patients with non-

«

'
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Hodgkin's disease were used.

The difference is significant.

When lymph node cells were used, all three incubation mix¬
tures containing cells from patients with Hodgkin's disease
released pyrogen, whereas only three of nine released pyrogen
when lymph node cells were from patients with non-Hodgkin’s
disease.

Th tdifference is significant.

Lymphoid tissue, from patients with Hodgkin's disease
has been shown to be capable of spontaneous and prolonged
endogenous pyrogen release ini vitro.

Some evidence has

been found suggesting that serum factors may modify this
capacity of tissue cells fro EP release in vitro.

Lympho¬

cyte preparations from these tissues appeared to have the
capacity to activate normal blood leukocytes to release
pyrogen.

These results suggest that the mechanism for

the spontaneous release of EP by spleen preparations may
involve the action of tissue lymphocytes on cells capable
of pyrogen release, as by elaboration of a lymphokine.
They further suggest that fever in Hodgkin's disease may
result from the abnormal behavior of lymphoid tissue cells.
as demonstrated in vitro.
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